194 related articles for article (PubMed ID: 29744290)
1. Identification of small-molecule elastase inhibitors as antagonists of IL-36 cytokine activation.
Sullivan GP; Davidovich PB; Sura-Trueba S; Belotcerkovskaya E; Henry CM; Clancy DM; Zinoveva A; Mametnabiev T; Garabadzhiu AV; Martin SJ
FEBS Open Bio; 2018 May; 8(5):751-763. PubMed ID: 29744290
[TBL] [Abstract][Full Text] [Related]
2. Suppressing IL-36-driven inflammation using peptide pseudosubstrates for neutrophil proteases.
Sullivan GP; Henry CM; Clancy DM; Mametnabiev T; Belotcerkovskaya E; Davidovich P; Sura-Trueba S; Garabadzhiu AV; Martin SJ
Cell Death Dis; 2018 Mar; 9(3):378. PubMed ID: 29515113
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family Cytokines.
Henry CM; Sullivan GP; Clancy DM; Afonina IS; Kulms D; Martin SJ
Cell Rep; 2016 Feb; 14(4):708-722. PubMed ID: 26776523
[TBL] [Abstract][Full Text] [Related]
4. Production of biologically active IL-36 family cytokines through insertion of N-terminal caspase cleavage motifs.
Clancy DM; Henry CM; Davidovich PB; Sullivan GP; Belotcerkovskaya E; Martin SJ
FEBS Open Bio; 2016 Apr; 6(4):338-48. PubMed ID: 27239446
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin G cleaves and activates IL-36γ and promotes the inflammation of psoriasis.
Guo J; Tu J; Hu Y; Song G; Yin Z
Drug Des Devel Ther; 2019; 13():581-588. PubMed ID: 30804664
[TBL] [Abstract][Full Text] [Related]
6. Small Molecule IL-36γ Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis.
Todorović V; Su Z; Putman CB; Kakavas SJ; Salte KM; McDonald HA; Wetter JB; Paulsboe SE; Sun Q; Gerstein CE; Medina L; Sielaff B; Sadhukhan R; Stockmann H; Richardson PL; Qiu W; Argiriadi MA; Henry RF; Herold JM; Shotwell JB; McGaraughty SP; Honore P; Gopalakrishnan SM; Sun CC; Scott VE
Sci Rep; 2019 Jun; 9(1):9089. PubMed ID: 31235749
[TBL] [Abstract][Full Text] [Related]
7. Extracellular Neutrophil Proteases Are Efficient Regulators of IL-1, IL-33, and IL-36 Cytokine Activity but Poor Effectors of Microbial Killing.
Clancy DM; Sullivan GP; Moran HBT; Henry CM; Reeves EP; McElvaney NG; Lavelle EC; Martin SJ
Cell Rep; 2018 Mar; 22(11):2937-2950. PubMed ID: 29539422
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonist.
Macleod T; Doble R; McGonagle D; Wasson CW; Alase A; Stacey M; Wittmann M
Sci Rep; 2016 Apr; 6():24880. PubMed ID: 27101808
[TBL] [Abstract][Full Text] [Related]
9. Unprocessed Interleukin-36α Regulates Psoriasis-Like Skin Inflammation in Cooperation With Interleukin-1.
Milora KA; Fu H; Dubaz O; Jensen LE
J Invest Dermatol; 2015 Dec; 135(12):2992-3000. PubMed ID: 26203636
[TBL] [Abstract][Full Text] [Related]
10. Biology of IL-36 cytokines and their role in disease.
Gresnigt MS; van de Veerdonk FL
Semin Immunol; 2013 Dec; 25(6):458-65. PubMed ID: 24355486
[TBL] [Abstract][Full Text] [Related]
11. The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis.
Madonna S; Girolomoni G; Dinarello CA; Albanesi C
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284527
[TBL] [Abstract][Full Text] [Related]
12. Elevated sputum IL-36 levels are associated with neutrophil-related inflammation in COPD patients.
Li W; Meng X; Hao Y; Chen M; Jia Y; Gao P
Clin Respir J; 2021 Jun; 15(6):648-656. PubMed ID: 33559376
[TBL] [Abstract][Full Text] [Related]
13. Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease.
Boutet MA; Bart G; Penhoat M; Amiaud J; Brulin B; Charrier C; Morel F; Lecron JC; Rolli-Derkinderen M; Bourreille A; Vigne S; Gabay C; Palmer G; Le Goff B; Blanchard F
Clin Exp Immunol; 2016 May; 184(2):159-73. PubMed ID: 26701127
[TBL] [Abstract][Full Text] [Related]
14. The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases.
Walsh PT; Fallon PG
Ann N Y Acad Sci; 2018 Apr; 1417(1):23-34. PubMed ID: 27783881
[TBL] [Abstract][Full Text] [Related]
15. Function and Regulation of IL-36 Signaling in Inflammatory Diseases and Cancer Development.
Queen D; Ediriweera C; Liu L
Front Cell Dev Biol; 2019; 7():317. PubMed ID: 31867327
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity.
Towne JE; Renshaw BR; Douangpanya J; Lipsky BP; Shen M; Gabel CA; Sims JE
J Biol Chem; 2011 Dec; 286(49):42594-42602. PubMed ID: 21965679
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γ.
Ainscough JS; Macleod T; McGonagle D; Brakefield R; Baron JM; Alase A; Wittmann M; Stacey M
Proc Natl Acad Sci U S A; 2017 Mar; 114(13):E2748-E2757. PubMed ID: 28289191
[TBL] [Abstract][Full Text] [Related]
18. IL-1α and IL-36 Family Cytokines Can Undergo Processing and Activation by Diverse Allergen-Associated Proteases.
Frezza V; Najda Z; Davidovich P; Sullivan GP; Martin SJ
Front Immunol; 2022; 13():879029. PubMed ID: 35844537
[TBL] [Abstract][Full Text] [Related]
19. IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis.
Bridgewood C; Fearnley GW; Berekmeri A; Laws P; Macleod T; Ponnambalam S; Stacey M; Graham A; Wittmann M
Front Immunol; 2018; 9():200. PubMed ID: 29535706
[TBL] [Abstract][Full Text] [Related]
20. Interleukin(IL)-36α and IL-36γ Induce Proinflammatory Mediators from Human Colonic Subepithelial Myofibroblasts.
Kanda T; Nishida A; Takahashi K; Hidaka K; Imaeda H; Inatomi O; Bamba S; Sugimoto M; Andoh A
Front Med (Lausanne); 2015; 2():69. PubMed ID: 26442271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
